MBX-2982 shows positive results in phase II clinical trials of type 2 diabetes by successfully reducing postprandial glucose levels in type 2 diabetes mellitus (T2DM) patients, and increases insulin and incretin levels in a 4-week phase II clinical trial (ClinicalTrials.gov Identifier: NCT01035879). Here, INS is linked to type 2 diabetes mellitus.